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important genes, among them E-cadherin, playing an important
role for sensitivity of EGFR TKIs.11
We conclude that while both increased EGFR gene copy num-
ber, EGFR gene mutations and over expression of EGFR protein all
associate with high response rates in NSCLC patients after EGFR
TKI therapy, only increased EGFR gene copy number by FISH
and EGFR protein expression seems to be independent predictive
factors for sensitivity to EGFR inhibitors. Patients without
increased EGFR gene copy number and lack of EGFR protein over
expression do most likely not have any clinical benefit from these
treatments.
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Two years have elapsed since mutations of the tyrosine kinase
domain of the EGFR were discovered in patients with NSCLC,
who had dramatic clinical responses to treatment with gefiti-
nib.1–3 Additional laboratory studies have provided further
insights into the biological impact of EGFR mutations and several
clinical observations have in retrospect confirmed the association
between mutations and response to the TKIs gefinitib and erloti-
nib.4 At the same time there is the suggestion that K-ras muta-
tions predict unresponsiveness to these TKIs and the fact that
K-ras mutations and EGFR mutations seem to be mutually exclu-
sive fits well in this concept.5 To validate the use of mutation sta-
tus for therapeutic decisions, we have conducted a study in which
the mutation status was determined prospectively, i.e. before the
start of treatment with TKIs.
Between June 2004 and December 2005 patients with locally
advanced or metastatic NSCLC were asked for their consent to
analyze diagnostic specimens for EGFR mutations, if they had
two out of three of the following characteristics: female gender,
non-smoking status and the diagnosis of BAC or adenocarcinoma.
Patients with a mutation in the EGFR TK domain were offered
treatment with erlotinib or gefitinib within the framework of
the compassionate use programs for these agents.
Baseline assessment included medical history (including prior
anticancer therapy), smoking history, physical examination and
vital signs, PS, complete blood cell count and blood biochemistry,
chest X-ray and tumor assessment (X-rays or computed tomogra-
phy scans). At follow-up (every 4–6 weeks), interval history, chest
X-ray, tumor assessment, complete blood count and biochemistry
were collected. Response was determined using the RECIST criteria.
We determined EGFR and K-Ras mutations by isolating DNA
from formalin-fixed paraffin embedded tumor biopsies. For EGFR
mutation analysis, exons 18–21 were PCR amplified using exon
specific primers. Since the samples were often small (biopsies)
and formalin fixed, primers were designed located in the flanking
introns, such that the size of the PCR fragments was reduced
compared to most published primers. K-ras mutation analysis
of codon 12 was performed as above.
Forty-one patients were selected for the assessment of muta-
tion status. Thirteen (out of 41 = 32%) biopsies were found to con-
tain an EGFR mutation. None of them had a K-ras mutation. The
median age of the mutation positive patients was 55, three of
them were ex-smokers and 10 were never smokers. Six of them
were male. All but four patients were chemonaive. Nine out of
the thirteen patients with mutations in the EGFR gene had an
in-frame deletion. In seven cases this was a 15 bp deletion in exon
19. The remaining four patients had a point mutation, in three
cases located in exon 21 and in one case there were 2 point muta-
tions in exon 18.
All patients with an exon 19 deletion had a swift response on
erlotinib or gefitinib. So did three out of four patients presenting
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with a point mutation. Two patients with point mutations eventu-
ally experienced progression of their disease. Tumor progression
was not observed in the patients with exon 19 deletions. The
mean progression free interval was 430 days (CI [294,567]) for
the whole series.
Conclusions: The observations add support to the importance of
EGFR status as predictors of response to TKIs. Exon 19 deletions
seem to predict the best responses to TKIs.
doi:10.1016/j.ejcsup.2006.04.030
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RECEPTOR 9 WITH PF-3512676 (FORMERLY CPG 7909)
Arthur M. Krieg. Coley Pharmaceutical Group.
Unmethylated CpG dinucleotides are relatively common in viral
and bacterial DNA, but are rare in vertebrate DNA. Toll-like
receptor 9 (TLR9) detects these ‘‘CpG motifs’’ as a sign of infec-
tion, and can be activated for therapeutic purposes by CpG
motifs in synthetic oligodeoxynucleotides (CpG ODN), such as
PF-3512676 (formerly called CPG 7909, or CpG 2006). PF-3512676
engages TLR9 in B cells and plasmacytoid dendritic cells (pDC),
thereby stimulating innate and adaptive immunity, including
antigen-specific Th1-like T cell responses. Murine studies
showed anti-tumor activity of PF-3512676 as a monotherapy
for relatively small tumors. Tumor regression was associated
with the induction of a tumor-specific CTL response. PF-
3512676 has been administered at various dose levels to more
than 1000 humans, and has shown activity as a monotherapy
in phase I human clinical trials when administered by intratu-
moral injection in basal cell carcinoma, by subcutaneous injec-
tion in cutaneous T cell lymphoma (CTCL), melanoma, and
renal cell carcinoma, and by intravenous injection in non-Hodg-
kin’s lymphoma.
Although the demonstrated activity as a monotherapy pro-
vides some proof-of-concept for the use of PF-3512676 in cancer
therapy, we considered that combination approaches may pro-
vide greater efficacy. We theorized that disruption of the tumor
using conventional anti-tumor therapies may reduce the
tumors’ resistance to immune mediated attack induced through
TLR9 activation with PF-3512676. In murine models regression of
larger tumors could be induced when PF-3512676 was used in
combination with other therapies, including radiotherapy, surgi-
cal resection, monoclonal anti-tumor antibodies, and chemo-
therapy. The combination of PF-3512676 or other CpG ODN
with certain chemotherapy regimens, including paclitaxel or
gemcitabine, increased the generation of tumor antigen-specific
CTL and/or improved tumor regression and survival in meta-
static tumor models. These studies also demonstrated the
involvement of T cells in the synergy between CpG and paclit-
axel, consistent with the hypothesis that this combination
induces enhanced tumor specific adaptive immune responses.
These encouraging results in mouse models have been extended
into human therapy in a controlled Phase II trial, where 112
patients with locally advanced or metastatic non-small cell lung
cancer were randomized to receive either chemotherapy alone,
or in combination with PF-3512676. The combination with che-
motherapy provided a statistically significant improvement in
objective response rate, and a trend to prolonged survival (1 year
survival 33% vs. 50%, P = 0.08). The safety and tolerability of
these TLR9 agonists has generally been good, with the major
adverse events being transient injection site reactions and flu-
like symptoms. Phase III trials of PF-3512676 in combination
with 2 doublet chemotherapy regimens (paclitaxel plus carbo-
platin or gemcitabine plus cisplatin) for first-line therapy of
locally advanced or metastatic NSCLC in 1600 patients were ini-
tiated in late 2005.
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In the mid 1990s one of the first targets of DNA microarray analysis
was melanoma. For over a decade researchers have made increas-
ing use of this technology in their efforts to understand the molec-
ular biology underlying this disease. Most work has concentrated
on class-comparison approaches which assess the transcriptional
differences between aggressive and less aggressive variants, or
explored the consequences of activating mutations in members
of the MAPK pathway. Other studies examined the effects of vari-
ous in vitro treatments including UV, retinoids, demethylation and
hypoxia. The general outcome of these studies have been the gen-
eration of ever longer lists of genes nearly all of which are guilty
through association. But who are the master criminals in the
crowd? Where are the strings which draw these multitudinous
factors together and who are the puppetmasters behind them?
DNA microarrays may have brought us closer to the facts, but
what they all mean is not at all obvious to the majority of research-
ers. Just where in these details lies the devil of malignancy?
doi:10.1016/j.ejcsup.2006.04.032
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Immunotherapy has been widely investigated for its potential
use in cancer therapy and it becomes more and more apparent
that the selection of target antigens is essential for its efficacy.
Indeed, limited clinical efficacy is partly due to immune eva-
sion mechanisms of neoplastic cells, e.g. downregulation of
expression or presentation of the respective antigens. Conse-
quently, antigens contributing to tumor cell survival seem to
be more suitable therapeutic targets. However, even such
antigens may be subject to immune evasion due to impaired
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